Revolutionary Wireless Vagus Nerve Stimulator Brings Medical-Grade Wellness Technology to Consumer Market
Vagal oh! Introduces Ultra-Compact Device Featuring Breakthrough EverSteady Technology for Safe, Non-Invasive Nerve Stimulation [San Diego, September 10th] – Vagal.com, a leader in accessible vagus nerve stimulation technology, today announced the launch of Vagal Oh!, a ground-breaking wireless, non-invasive vagus nerve stimulator that represents a quantum leap in personal wellness technology. The ultra-compact device incorporates proprietary EverSteady technology, establishing a new gold standard for safe consumer nerve stimulation. Breaking the Size Barrier in Wellness Technology At just 23mm, Vagal oh! is the world’s smallest wireless vagus nerve stimulator, making advanced wellness technology truly portable without compromising effectiveness. The device’s revolutionary miniaturization represents years of engineering innovation, bringing medical-grade nerve stimulation capabilities to a form factor smaller than most fitness trackers. “We’ve fundamentally reimagined what’s possible in vagus nerve stimulation,” said Hannah, Customer Relations at Vagal.com “Vagal Oh! proves that cutting-edge wellness technology doesn’t require bulky equipment or complex setups. This is vagus nerve stimulation made beautifully simple.” EverSteady Technology: The New Gold Standard The device’s cornerstone innovation, EverSteady technology, addresses the primary safety concerns that have limited consumer access to vagus nerve stimulation. This proprietary system automatically monitors and adjusts stimulation parameters in real-time, ensuring optimal therapeutic benefit while maintaining the highest safety standards. EverSteady technology features: Adaptive Current Regulation: Automatically adjusts stimulation intensity based on individual physiological responses Continuous Safety Monitoring: Real-time impedance checking prevents overstimulation Precision Targeting: Advanced algorithms ensure stimulation reaches optimal nerve pathways Zero-Drift Guarantee: Maintains consistent therapeutic parameters throughout each session Clinical Foundation Meets Consumer Accessibility Vagus nerve stimulation has been extensively studied for its benefits on stress reduction, sleep quality, mood regulation, and overall wellness. However, previous devices required clinical settings or complex home installations. Vagal oh! democratizes this technology, making it accessible to anyone seeking to optimize their autonomic nervous system. “The vagus nerve is essentially your body’s reset button,” explained Dr. Brown, an independent neurologist specializing in autonomic disorders. “What Vagal has achieved with EverSteady technology is remarkable – they’ve made this powerful therapeutic modality both safe and simple enough for daily home use.” Market Impact and Availability The wellness technology market has seen unprecedented growth, with consumers increasingly seeking evidence-based solutions for stress management and overall health optimization. Vagal Oh! enters this market with a unique value proposition: medical-grade efficacy in an ultra-portable, user-friendly package. Key market differentiators include: Wireless Freedom: No cables, electrodes, or complex setup requirements Ultra-Portable Design: Fits easily in pocket or purse for wellness on-the-go Medical-Grade Safety: EverSteady technology ensures clinical-level safety standards Consumer-Friendly: Designed for daily use by wellness enthusiasts, not medical professionals About Vagal Founded on the principle of making advanced wellness technology accessible to all, Vagal has been pioneering consumer vagus nerve stimulation solutions since 2019. The company’s mission, “Vagally Better,” reflects its commitment to improving lives through innovative nerve stimulation technology. Vagal’s products combine rigorous scientific research with elegant design, bringing clinical-grade wellness solutions to the consumer market. Ordering Information Vagal Oh! is available for immediate order through vagal.com. Early adopters can take advantage of introductory pricing and free shipping worldwide. Order now at Vagal.com Media Contact: Hannah Vagal Phone: +1 678 VAGALLY Email: [email protected] Website: https://vagal.com High-resolution images, technical specifications, and interview opportunities available upon request. About This Release: This press release contains forward-looking statements about Vagal’s products and technology. While based on current research and development, individual results may vary. Vagal oh! is designed for wellness purposes and is not intended to diagnose, treat, cure, or prevent any disease.
How UC’s Innovative Work is Helping to Prevent Concussion
The sports world is putting more attention on the widespread incidence of concussion, especially among young contact-sport players. Christmas Day saw the premiere of the movie “Concussion” with actor Will Smith as Pittsburgh forensic pathologist Bennet Omalu, who first drew the conclusion about athletes’ repeated concussion leading to chronic brain trauma. This year, the UC Health Department of Orthopaedics & Sports Medicine has pushed forward the body of knowledge on concussion. UC neurologist Joseph Clark, also a certified athletic trainer in the department, published the nation’s first study on how to drastically reduce the number of concussions among athletes. Medium: Cincinnati Enquirer Read the article »
Generic vs. Brand-Name Anti-Epileptic Drugs
The generic versus brand-name drug debate has long been a hot-button issue in the epilepsy community. But the findings of research presented at the American Epilepsy Society’s Annual Meeting revealed that brand-name and generic formulations of anti-epileptic drugs (AED) are, for all intents and purposes, the same. Medium: Neurology Times Read the article »
Walk Ahead Event to Stop Brain Tumors
In this segment, Medical Edge reporter Liz Bonis interviews Billi Ewing, survivor of an atypical meningioma brain tumor, about her experience and why she’s participating in the Walk Ahead for a Brain Tumor Cure. Dr. David Plas, a researcher at the UC Brain Tumor Center and UC Cancer Institute, discusses some of the ways research is making a difference. Medium: Local 12 WKRC Watch the segment »
Hear All About the Walk Ahead Event
Luke Pater, MD, a radiation oncologist with the UC Brain Tumor Center, and brain tumor survivor Tom Blankemeyer discuss how Walk Ahead for a Brain Tumor Cure propels local research and gives families and friends a chance to get involved. Medium: News 5 WLWT Watch the segment »
UC Brain Science Unit Launches Push for Own Building
In a bold effort to place the University of Cincinnati’s sprawling brain-science practice under one roof, writes Anne Saker of the Cincinnati Enquirer, officials of the UC Neuroscience Institute announced Friday a $54.6 million campaign to build a dedicated facility for the study and treatment of disorders such as Parkinson’s disease, stroke and epilepsy. Media: Cincinnati.com Read the article >
Here’s Why Concussions Plummeted Among UC Football Players
The number of concussions suffered by University of Cincinnati football players has dropped by more than 80 percent since an innovative peripheral-vision training program started five years ago, according to UC researchers. Medium: Cincinnati Business Courier Read the article »
Doctors are Using Advanced New Devices to Treat Stroke Patients
Dr. Andrew Ringer, endovascular neurosurgeon at the UC Comprehensive Stroke Center, explains how doctors are using an elegant new generation of clot-retrieval devices to help patients who suffer blockages in large blood vessels. Media: WCPO.com Watch/read the segment >
Stroke Survivor to Walk in Heart Mini
Terri Kersey, who suffered a stroke in Africa while raising money for charity, will be walking in the “Steps for Stroke” event in the upcoming American Heart Association’s Heart Mini. Media: Local 12 WKRC-TV Watch the segment >
Can Medical Marijuana Combat Epilepsy? Cincinnati Scientists Seek Answer
Separate clinical trials to determine whether medical marijuana can help ward off seizures in people with epilepsy will begin soon at the University of Cincinnati and Cincinnati Children’s Hospital Medical Center. Michael Privitera, MD, Medical Director of the Epilepsy Center at the UC Neuroscience Institute, will be the lead investigator. Media: Cincinnati Business Courier Read the article »